IN8bio, Inc. (6JH.MU)

0.9450 0.0000 (0.00%) At close: 08:03AM CEST

IN8bio, Inc.

350 5th Avenue
Suite 5330
New York, NY 10118
United States
646 600 6438
https://in8bio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 31

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Tai-Wei Ho	Co-Founder, President, CEO & Director	809.3k	N/A	1977
Mr. Patrick McCall CPA	CFO & Secretary	550.02k	N/A	1984
Dr. Trishna Goswami M.D.	Chief Medical Officer	621.87k	N/A	1979
Dr. Lawrence S. Lamb Ph.D.	Executive VP, Co-Founder & Chief Scientific Officer	448.81k	N/A	1955
Dr. Kate Rochlin Ph.D.	Chief Operating Officer	525.95k	N/A	1982
Mr. Michael McNamara	Vice President of Accounting	N/A	N/A	N/A
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.	VP and Head of IR & Corporate Communications	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

Corporate governance

IN8bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.